Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients

Investigational New Drugs

Volumn 22, Issue 3, 2004, Pages 285-289

  Sparreboom, Alex ^a   Marsh, Sharon ^b   Mathijssen, Ron H J ^c   Verweij, Jaap ^c   McLeod, Howard L ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Pharmacogenetics; Polymorphisms; R115777; Tipifarnib

Indexed keywords

ABC TRANSPORTER; CARRIER PROTEIN; CARRIER PROTEIN ABCB1; CYTOCHROME P450; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 ISOENZYME; DRUG METABOLIZING ENZYME; GLUCURONOSYLTRANSFERASE; GLYCOPROTEIN P; IRINOTECAN; ISOENZYME; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE;

ADULT; ADVANCED CANCER; AGED; ALLELE; AREA UNDER THE CURVE; BLOOD SAMPLING; CANCER PATIENT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONFERENCE PAPER; CORRELATION ANALYSIS; DRUG EXPOSURE; DRUG METABOLISM; DRUG TRANSPORT; FEMALE; GENE CASSETTE; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; MALE; MEASUREMENT; PHARMACOGENETICS; PRIORITY JOURNAL; SOLID TUMOR; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, GENETIC; QUINOLONES; TANDEM REPEAT SEQUENCES;

EID: 3543031620     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DRUG.0000026254.97350.fe     Document Type: Conference Paper

References (21)

1. Wright JJ, Zerivitz K, Gravell AE: Clinical trials referral resource. Current clinical trials of R115777 (Zarnestra). Oncology (Huntingt) 16: 930-931, 935-937, 2002
2. End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61: 131-137, 2001
3. Kelland LR, Smith V, Valenti M, Patterson L, Clarke PA, Dette S, End D, Howes AJ, Dowsett M, Workman P, Johnston SR: Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res 7: 3544-3550, 2001
4. Van Cutsem E, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Neumann H, Safran H, Humblet Y, Van de Velde H, Ma Y, Von Hoff D: Phase III trial comparing gemcitabine + R115777 (Zarnestea) versus gemcitabine + placebo in advanced pancreatic cancer (PC). Proc Am Soc Clin Oncol 21: 2002, Abstract # 517
5. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J: Clinical and biologic activity of the famesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial. Blood 97: 3361-3369, 2001
6. Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A, Rackoff W, Koller C, O'Brien S, Garcia-Maneo G, Talpaz M, Kantarjian H: Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 101: 1692-1697, 2003
7. Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB, Cowan KH: Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 18: 927-941, 2000
8. Crul M, De Klerk GJ, Swart M, Van't Veer LJ, De Jong D, Boerrigter L, Palmer PA, Bol CJ, Tan H, De Gast GC, Beijnen JH, Schellens JHM: Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 20: 2726-2735, 2002
9. 14C-labeled (R)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5- yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor. Drug Metab Dispos 30: 823-830, 2002
10. 14C-R115777 and on the effect of R115777 on the metabolism of specific human cytochrome P-450 substrates. Janssen Research Foundation, Non-clinical Pharmacokinetics Report R115777/FK2809, June 1998
11. Evans WE, McLeod HL: Pharmacogenomics - Drug disposition, drug targets, and side effects. N Engl J Med 348: 538-549, 2003
12. Verweij J, Kehrer DFS, Planting AST, De Jonge MJA, Eskens F, Klaren A, De Heus G, Palmer PA, Bol CJ, Sparreboom A: Phase I trial of irinotecan in combination with the farnesyl transferase inhibitor (FTI) R115777. Proc Am Soc Clin Oncol 20: 2001, Abstract #319
13. Mathijssen RHJ, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, McLeod HL: Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 9: 3246-3253, 2003
14. Van Schaik R, Van der Werf M, Van der Heiden IP, Dorrestein S, Brosens R, Thiadens A, Van Iperen N, Van Fessem M, Van Vliet M, De Wildt SN, Van den Anker J, Lindemans J: CYP3A4, CYP3A5 and MDR-1 variant alleles in the Dutch Caucasian population. Clin Pharmacol Ther 73: P42, 2003, Abstract #PII-49
15. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, Boer A, Oostra BA: The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333: 1171-1175, 1995
16. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, Lee CG: Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12: 437-450, 2002
17. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJD: Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13: 89-95, 2003
18. Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD: Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resis Updates 266: 71-84, 2003
19. Smith V, Rowlands MG, Barrie E, Workman P, Kelland LR: Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line. Clin Cancer Res 8: 2002-2009, 2002
20. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, Matsuo M, Kasuga M, Okumura K: Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 71: 297-303, 2002
21. Goto M, Masuda S, Saito H, Uemoto S, Kiuchi T, Tanaka K, Inui K: C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 12: 451-457, 2002